Testosterone treatment to mimic hormone physiology in androgen replacement therapy

Bibliography

• ARAUJO AB, O'DONNELL AB, BRAMBILLA DJ et al.: Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts male ageing study. J. Clin. Endocrinol. Metab. (2004) 89(12):5920-5926.
   PubMed Web of Science ®Google Scholar
• ISIDORI AM, GIANNETTA E, GRECO EA et al.: Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin. Endocrinol. (Oxf). (2005) 63(3):280-293.
   PubMed Web of Science ®Google Scholar
• ISIDORI AM, GIANNETTA E, POZZA C, BONIFACIO V, ISIDORI A: Androgens, cardiovascular disease and osteoporosis. J. Endocrinol. Invest. (2005) 28(10 Suppl.):73-79.
   PubMedGoogle Scholar
• GOOREN L: Androgen deficiency in the ageing male: benefits and risks of androgen supplementation. J. Steroid Biochem. Mol. Biol. (2003) 85(2-5):349-355.
   PubMed Web of Science ®Google Scholar
• ISIDORI AM, GIANNETTA E, GIANFRILLI D et al.: Effects of testosterone on sexual function in men: results of a meta-analysis. Clin. Endocrinol. (Oxf). (2005) 63(4):381-394.
   PubMed Web of Science ®Google Scholar
• KORENMAN SG, MORLEY JE, MOORADIAN AD et al.: Secondary hypogonadism in older men: its relation to impotence. J. Clin. Endocrinol. Metab. (1990) 71(4):963-969.
   PubMed Web of Science ®Google Scholar
• KAUFMAN JM, VERMAULEN A: The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr. Rev. (2005) 26(6):833-876.
   PubMed Web of Science ®Google Scholar
• ISIDORI AM, LENZI A: Risk factors for androgen decline in older males: lifestyle, chronic diseases and drugs. J. Endocrinol. Invest. (2005) 28(3 Suppl.):14-22.
   PubMedGoogle Scholar
• ZIRKIN BR, CHEN H: Regulation of Leydig cell steroidogenic function during ageing. Biol. Reprod. (2000) 63(4):977-981.
   PubMed Web of Science ®Google Scholar
• ISIDORI AM, CAPRIO M, STROLLO F et al.: Leptin and androgens in male obesity: evidence for leptin contribution to reduced androgen levels. J. Clin. Endocrinol. Metab. (1999) 84(10):3673-3680.
   PubMed Web of Science ®Google Scholar
• ISIDORI AM, STROLLO F, MORE M et al.: Leptin and ageing: correlation with endocrine changes in male and female healthy adult populations of different body weights. J. Clin. Endocrinol. Metab. (2000) 85(5):1954-1962.
   PubMed Web of Science ®Google Scholar
• ALGARTE-GENIN M, CUSSENOT O, COSTA P: Prevention of prostate cancer by androgens: experimental paradox or clinical reality. Eur. Urol. (2004) 46(3):285-294.
   PubMed Web of Science ®Google Scholar
• NIESCHLAG E, BEHRE HM, BOUCHARD P et al.: Testosterone replacement therapy: current trends and future directions. Hum. Reprod. Update (2004) 10(5):409-419.
   PubMed Web of Science ®Google Scholar
• KELLER ET, ERSHLER WB, CHANG C: The androgen receptor: a mediator of diverse responses. Front. Biosci. (1996) 1:D59-D71.
   PubMedGoogle Scholar
• GUO Z, BENTEN WP, KRUCKEN J et al.: Nongenomic testosterone calcium signaling. Genotropic actions in androgen receptor-free macrophages. J. Biol. Chem. (2002) 277(33):29600-29607.
   PubMed Web of Science ®Google Scholar
• HIJAZI RA, CUNNINGHAM GR: Andropause: is androgen replacement therapy indicated for the ageing male? Ann. Rev. Med. (2005):56117-56137.
   Google Scholar
• HARMAN SM, METTER EJ, TOBIN JD, PEARSON J, BLACKMAN MR: Longitudinal effects of ageing on serum total and free testosterone levels in healthy men. J. Clin. Endocrinol. Metab. (2001) 86(2):724-731.
   PubMed Web of Science ®Google Scholar
• BARTSCH G, RITTMASTER G, KLOCKER H: Dihydrotestosterone and the concept of 5α-reductase inhibition in human prostatic benign hyperplasia. World J. Urol. (2002) 19(6):413-425.
   PubMed Web of Science ®Google Scholar
• LY LP, JIMENEZ M, ZHUANG TN et al.: A double-blind, placebo-controlled, randomized clinical trial of transdermal dihydrotestosterone gel on muscular strength, mobility, and quality of life in older men with partial androgen deficiency. J. Clin. Endocrinol. Metab. (2001) 86(9):4078-4088.
   PubMed Web of Science ®Google Scholar
• HANDELSMAN DJ, CONWAY AJ, BOYLAN LM: Pharmacokinetics and pharmacodynamics of testosterone pellets in man. J. Clin. Endocrinol. Metab. (1990) 71(1):216-222.
   PubMed Web of Science ®Google Scholar
• HANDELSMAN DJ, MACKEY MA, HOWE C, TURNER L, CONWAY AJ: An analysis of testosterone implants for androgen replacement therapy. Clin. Endocrinol. (Oxf). (1997) 47(3):311-316.
   PubMed Web of Science ®Google Scholar
• BEHRE HM, ABSHAGEN K, OETTEL M, HUBLER D, NIESCHLAG E: Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: Phase I studies. Eur. J. Endocrinol. (1999) 140(5):414-419.
   PubMed Web of Science ®Google Scholar
• BEHRE HM, NIESCHLAG E: Testosterone buciclate (20 Aet-1) in hypogonadal men: pharmacokinetics and pharmacodynamics of the new long-acting androgen ester. J. Clin. Endocrinol. Metab. (1992) 75(5):1204-1210.
   PubMed Web of Science ®Google Scholar
• SNYDER PJ, LAWRENCE DA: Treatment of male hypogonadism with testosterone enantate. J. Clin. Endocrinol. Metab. (1980) 51(6):1335-1339.
   PubMed Web of Science ®Google Scholar
• DOBS AS, MEIKLE AW, ARVER S et al.: Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enantate for the treatment of hypogonadal men. J. Clin. Endocrinol. Metab. (1999) 84(10):3469-3478.
   PubMed Web of Science ®Google Scholar
• VON ECKARDSTEIN S, NIESCHLAG E: Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a Phase II study. J. Androl. (2002) 23(3):419-425.
   PubMed Web of Science ®Google Scholar
• NADELL J, KOSEK J: Peliosis hepatis. Twelve cases associated with oral androgen therapy. Arch. Pathol. Lab. Med. (1977) 101(8):405-410.
   PubMed Web of Science ®Google Scholar
• OVERLY WL, DANKOFF JA, WANG BK, SINGH UD: Androgens and hepatocellular carcinoma in an athlete. Ann. Intern. Med. (1984) 100(1):158-159.
   PubMed Web of Science ®Google Scholar
• WESTABY D, OGLE SJ, PARADINAS FJ, RANDELL JB, MURRAY-LYON IM: Liver damage from long-term methyltestosterone. Lancet (1977) 2(8032):262-263.
   PubMed Web of Science ®Google Scholar
• GOOREN LJ: A ten-year safety study of the oral androgen testosterone undecanoate. J. Androl. (1994) 15(3):212-215.
   PubMed Web of Science ®Google Scholar
• BOYANOV MA, BONEVA Z, CHRISTOV VG: Testosterone supplementation in men with Type 2 diabetes, visceral obesity and partial androgen deficiency. Ageing Male (2003) 6(1):1-7.
   PubMedGoogle Scholar
• MARIN P, HOLMANG S, JONSSON L et al.: The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int. J. Obes. Relat. Metab. Disord. (1992) 16(12):991-997.
   PubMed Web of Science ®Google Scholar
• PARK NC, YAN BQ, CHUNG JM, LEE KM: Oral testosterone undecanoate (Andriol) supplement therapy improves the quality of life for men with testosterone deficiency. Aging Male (2003) 6(2):86-93.
   PubMedGoogle Scholar
• UYANIK BS, ARI Z, GUMUS B et al.: Beneficial effects of testosterone undecanoate on the lipoprotein profiles in healthy elderly men. A placebo-controlled study. Jpn. Heart J. (1997) 38(1):73-82.
   PubMedGoogle Scholar
• WITTERT GA, CHAOMAN IM, HAREN MT et al.: Oral testosterone supplementation increases muscle and decreases fat mass in healthy elderly males with low-normal gonadal status. J. Gerontol. A Biol. Sci. Med. Sci. (2003) 58(7):618-625.
   PubMed Web of Science ®Google Scholar
• BEHRE HM, VON ECKARDSTEIN S, KLIESCH S, NIESCHLAG E: Long-term substitution therapy of hypogonadal men with transscrotal testosterone over 7 – 10 years. Clin. Endocrinol. (Oxf). (1999) 50(5):629-635.
   PubMed Web of Science ®Google Scholar
• CUNNINGHAM GR, CORDERO E, THORNBY JI: Testosterone replacement with transdermal therapeutic systems. Physiological serum testosterone and elevated dihydrotestosterone levels. JAMA (1989) 261(17):2525-2530.
   PubMed Web of Science ®Google Scholar
• DANIELL HW, LENTZ R, MAZER NA: Open-label pilot study of testosterone patch therapy in men with opioid-induced androgen deficiency. J. Pain (2006) 7(3):200-210.
   PubMed Web of Science ®Google Scholar
• SNYDER PJ, PAECHEY H, HANNOUSH P et al.: Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J. Clin. Endocrinol. Metab. (1999) 84(8):2647-2653.
   PubMed Web of Science ®Google Scholar
• SNYDER PJ, PAECHEY H, HANNOUSH P et al.: Effect of testosterone treatment on bone mineral density in men over 65 years of age. J. Clin. Endocrinol. Metab. (1999) 84(6):1966-1972.
   PubMed Web of Science ®Google Scholar
• SNYDER PJ, PAECHEY H, BERLIN JA et al.: Effect of transdermal testosterone treatment on serum lipid and apolipoprotein levels in men more than 65 years of age. Am. J. Med. (2001) 111(4):255-260.
   PubMed Web of Science ®Google Scholar
• MEIKLE AW, ARVER S, DOBS AS et al.: Pharmacokinetics and metabolism of a permeation-enhanced testosterone transdermal system in hypogonadal men: influence of application site – a clinical research center study. J. Clin. Endocrinol. Metab. (1996) 81(5):1832-1840.
   PubMed Web of Science ®Google Scholar
• WANG C, SWERDLOFF R, KIPNES M et al.: New testosterone buccal system (Striant) delivers physiological testosterone levels: pharmacokinetics study in hypogonadal men. J. Clin. Endocrinol. Metab. (2004) 89(8):3821-3829.
   PubMed Web of Science ®Google Scholar
• KORBONITS M, SLAWIK M, CULLEN D et al.: A comparison of a novel testosterone bioadhesive buccal system, striant, with a testosterone adhesive patch in hypogonadal males. J. Clin. Endocrinol. Metab. (2004) 89(5):2039-2043.
   PubMed Web of Science ®Google Scholar
• ROSS RJ, JABBAR A, JONES TH et al.: Pharmacokinetics and tolerability of a bioadhesive buccal testosterone tablet in hypogonadal men. Eur. J. Endocrinol. (2004) 150(1):57-63.
   PubMed Web of Science ®Google Scholar
• DOBS AS, MATSUMOTO AM, WANG C, KIPNES MS: Short-term pharmacokinetic comparison of a novel testosterone buccal system and a testosterone gel in testosterone deficient men. Curr. Med. Res. Opin. (2004) 20(5):729-738.
   PubMed Web of Science ®Google Scholar
• GOOREN LJ, BUNCK MC: Transdermal testosterone delivery: testosterone patch and gel. World J. Urol. (2003) 21(5):316-319.
   PubMed Web of Science ®Google Scholar
• JOCKENHOVEL F: Testosterone supplementation: what and how to give. Ageing Male (2003) 6(3):200-206.
   PubMedGoogle Scholar
• BASARIA S, DOBS AS: New modalities of transdermal testosterone replacement. Treat. Endocrinol. (2003) 2(1):1-9.
   PubMedGoogle Scholar
• WANG C, SWEDLOFF RS, IRANMANESH A et al.: Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. Testosterone Gel Study Group. J. Clin. Endocrinol. Metab. (2000) 85(8):2839-2853.
   PubMed Web of Science ®Google Scholar
• KUHNERT B, BYRNE M, SIMONI M et al.: Testosterone substitution with a new transdermal, hydroalcoholic gel applied to scrotal or non-scrotal skin: a multicentre trial. Eur. J. Endocrinol. (2005) 153(2):317-326.
   PubMed Web of Science ®Google Scholar
• MAZER N, BELL D, WU J et al.: Comparison of the steady-state pharmacokinetics, metabolism, and variability of a transdermal testosterone patch versus a transdermal testosterone gel in hypogonadal men. J. Sex Med. (2005) 2(2):213-226.
   PubMed Web of Science ®Google Scholar
• SWERDLOFF RS, WANG C, CUNNINGHAM G et al.: Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J. Clin. Endocrinol. Metab. (2000) 85(12):4500-4510.
   PubMed Web of Science ®Google Scholar
• WANG C, BERMAN N, LONGSTRETH JA et al.: Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a General Clinical Research Center Study. J. Clin. Endocrinol. Metab. (2000) 85(3):964-969.
   PubMed Web of Science ®Google Scholar
• WANG C, IRANMANESH A, BERMAN N et al.: Comparative pharmacokinetics of three doses of percutaneous dihydrotestosterone gel in healthy elderly men – a clinical research center study. J. Clin. Endocrinol. Metab. (1998) 83(8):2749-2757.
   PubMed Web of Science ®Google Scholar
• MAZER N, FISHER D, FISCHER J et al.: Transfer of transdermally applied testosterone to clothing: a comparison of a testosterone patch versus a testosterone gel. J. Sex Med. (2005) 2(2):227-234.
   PubMed Web of Science ®Google Scholar
• DEAN JD, CARNEGIE C, RODZVILLA J, SMITH T: Long-term effects of testim(r) 1% testosterone gel in hypogonadal men. Rev. Urol. (2004) 6(Suppl. 6):S22-S29.
   PubMedGoogle Scholar
• STEIDLE C, SCHWATRZ S, JACOBY K, SEBREE T, SMITH T, BACHAND R; North American AA2500 T Gel Study Group: AA2500 testosterone gel normalizes androgen levels in ageing males with improvements in body composition and sexual function. J. Clin. Endocrinol. Metab. (2003) 88(6):2673-2681.
   PubMed Web of Science ®Google Scholar
• WANG C, SWEDLOFF RS, IRANMANESH A et al.: Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. Testosterone Gel Study Group. J. Clin. Endocrinol. Metab. (2000) 85(8):2839-2853.
   PubMed Web of Science ®Google Scholar
• WANG C, CUNNINGHAM G, DOBS A et al.: Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J. Clin. Endocrinol. Metab. (2004) 89(5):2085-2098.
   PubMed Web of Science ®Google Scholar
• POPE HG Jr, COHANE GH, KANAYAMA G, SIEGEL AJ, HUDSON JI: Testosterone gel supplementation for men with refractory depression: a randomized, placebo-controlled trial. Am. J. Psychiatry (2003) 160(1):105-111.
   PubMed Web of Science ®Google Scholar
• ORENGO CA, FULLERTON L, KUNIK ME: Safety and efficacy of testosterone gel 1% augmentation in depressed men with partial response to antidepressant therapy. J. Geriatr. Psychiatry Neurol. (2005) 18(1):20-24.
   PubMed Web of Science ®Google Scholar
• CARNAHAN RM, PERRY PJ: Depression in ageing men: the role of testosterone. Drugs Ageing (2004) 21(6):361-376.
   PubMed Web of Science ®Google Scholar
• MARGO K, WINN R: Testosterone treatments: why, when, and how? Am. Fam. Physician (2006) 73(9):1591-1598 (Review). Summary for patients in: Am. Fam. Physician (2006) 73(9):1603.
   PubMed Web of Science ®Google Scholar
• ROLF C, KNIE U, LEMMNITZ G, NIESCHLAG E: Interpersonal testosterone transfer after topical application of a newly developed testosterone gel preparation. Clin. Endocrinol. (Oxf). (2002) 56(5):637-641.
   PubMed Web of Science ®Google Scholar
• BUVAT J, LEMAIRE A: Endocrine screening in 1,022 men with erectile dysfunction: clinical significance and cost-effective strategy. J. Urol. (1997) 158(5):1764-1767.
   PubMed Web of Science ®Google Scholar
• JAIN P, RADEMAKER AW, MCVARY KT: Testosterone supplementation for erectile dysfunction: results of a meta-analysis. J. Urol. (2000) 164(2):371-375.
   PubMed Web of Science ®Google Scholar
• AVERSA A, ISIDORI AM, DE MARTINO MU et al.: Androgens and penile erection: evidence for a direct relationship between free testosterone and cavernous vasodilation in men with erectile dysfunction. Clin. Endocrinol. (Oxf). (2000) 53(4):517-522.
   PubMed Web of Science ®Google Scholar
• AVERSA A, ISIDORI AM, SPERA G, LENZI A, FABBRI A: Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction. Clin. Endocrinol. (Oxf). (2003) 58(5):632-638.
   PubMed Web of Science ®Google Scholar
• MORELLI A, FILIPPI S, MANCINA R et al.: Androgens regulate phosphodiesterase Type 5 expression and functional activity in corpora cavernosa. Endocrinology (2004) 145(5):2253-2263.
   PubMed Web of Science ®Google Scholar
• SHABSIGH R: The effects of testosterone on the cavernous tissue and erectile function. World J. Urol. (1997) 15(1):21-26.
   PubMed Web of Science ®Google Scholar
• REILLY CM, ZAMORANO P, STOPPER VS, MILLS TM: Androgenic regulation of NO availability in rat penile erection. J. Androl. (1997) 18(2):110-115.
   PubMed Web of Science ®Google Scholar
• ANDERSSON KE, HOLMQUIST F: Regulation of tone in penile cavernous smooth muscle. Established concepts and new findings. World J. Urol. (1994) 12(5):249-261.
   PubMed Web of Science ®Google Scholar
• BURNETT AL: The role of nitric oxide in erectile dysfunction: implications for medical therapy. J. Clin. Hypertens. (Greenwich) (2006) 8(12 Suppl. 4):53-62.
   PubMedGoogle Scholar
• WEBB CM, MCNEILL JG, HAYWARD CS, DE ZEIGLER D, COLLINS P: Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. Circulation (1999) 100(16):1690-1696.
   PubMed Web of Science ®Google Scholar
• CHOU TM, SUDHIR K, HUTCHISON SJ et al.: Testosterone induces dilation of canine coronary conductance and resistance arteries in vivo. Circulation (1996) 94(10):2614-2619.
   PubMed Web of Science ®Google Scholar
• HEINLEIN CA, CHANG C: The roles of androgen receptors and androgen-binding proteins in nongenomic androgen actions. Mol. Endocrinol. (2002) 16(10):2181-2187.
   PubMed Web of Science ®Google Scholar
• HWANG TI, CHEN HE, TSAI TF, LIN YC: Combined use of androgen and sildenafil for hypogonadal patients unresponsive to sildenafil alone. Int. J. Impot. Res. (2006) 18(4):400-404.
   PubMed Web of Science ®Google Scholar
• KALINCHENKO SY, KOZLOV GI, GONTCHAROV NP, KATSIYA GV: Oral testosterone undecanoate reverses erectile dysfunction associated with diabetes mellitus in patients failing on sildenafil citrate therapy alone. Ageing Male (2003) 6(2):94-99.
   PubMedGoogle Scholar
• ROSENTHAL BD, MAY NR, METRO MJ, HARKAWAY RC, GINSBERG PC: Adjunctive use of AndroGel (testosterone gel) with sildenafil to treat erectile dysfunction in men with acquired androgen deficiency syndrome after failure using sildenafil alone. Urology (2006) 67(3):571-574.
   PubMed Web of Science ®Google Scholar
• SHAMLOUL R, GHANEM H, FAHMY I et al.: Testosterone therapy can enhance erectile function response to sildenafil in patients with PADAM: a pilot study. J. Sex Med. (2005) 2(4):559-564.
   PubMed Web of Science ®Google Scholar
• ISIDORI AM, GRECO EA, AVERSA A: Androgen deficiency and hormone-replacement therapy. BJU Int. (2005) 96(2):212-216.
   PubMed Web of Science ®Google Scholar
• ARVER S, DOBS AS, MEIKLE AW et al.: Improvement of sexual function in testosterone deficient men treated for 1 year with a permeation enhanced testosterone transdermal system. J. Urol. (1996) 155(5):1604-1608.
   PubMed Web of Science ®Google Scholar
• SHABSIGH R, KAUFMAN JM, STEIDLE C, PADMA-NATHAN H: Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J. Urol. (2004) 172(2):658-663.
   PubMed Web of Science ®Google Scholar
• NIESCHLAG E, SWERDLOFF R, BEHRE HM et al.: Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations. Int. J. Androl. (2005) 28(3):125-127.
   PubMed Web of Science ®Google Scholar
• MARBURY T, HAMILL E, BACHAND R, SEBREE T, SMITH T: Evaluation of the pharmacokinetic profiles of the new testosterone topical gel formulation, Testim trade mark, compared to AndroGel(R). Biopharm. Drug Dispos. (2003) 24(3):115-120.
   PubMed Web of Science ®Google Scholar
• MCNICHOLAS TA, DEAN JD, MULDER H, CARNEGIE C, JONES NA: A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function. BJU Int. (2003) 91(1):69-74.
   PubMed Web of Science ®Google Scholar
• STEIDLE C, SCHWARTZ S, JACOBY K et al.: AA2500 testosterone gel normalizes androgen levels in ageing males with improvements in body composition and sexual function. J. Clin. Endocrinol. Metab. (2003) 88(6):2673-2681.
   PubMed Web of Science ®Google Scholar
• McGRIFF-LEE NJ: Transdermal testosterone gel (Cellegy). Curr. Opin. Investig. Drugs (2002) 3(11):1629-1632.
   PubMedGoogle Scholar
• JORDAN WP Jr: Allergy and topical irritation associated with transdermal testosterone administration: a comparison of scrotal and nonscrotal transdermal systems. Am. J. Contact Dermat. (1997) 8(2):108-113.
   PubMedGoogle Scholar
• ROLF C, GOTTSCHALK I, BEHRE HM et al.: Pharmacokinetics of new testosterone transdermal therapeutic systems in gonadotropin-releasing hormone antagonist-suppressed normal men. Exp. Clin. Endocrinol. Diabetes (1999) 107(1):63-69.
   PubMed Web of Science ®Google Scholar
• MILLER KK, ROSNER W, LEE H et al.: Measurement of free testosterone in normal women and women with androgen deficiency: comparison of methods. J. Clin. Endocrinol. Metab. (2004) 89(2):525-533.
   PubMed Web of Science ®Google Scholar
• WU FC: Commentary: guideline for male testosterone therapy: a European perspective. J. Clin. Endocrinol. Metab. (2007) 92(2):418-419.
   PubMed Web of Science ®Google Scholar
• MORGENTALER A: Commentary: guideline for male testosterone therapy: a clinician's perspective. J. Clin. Endocrinol. Metab. (2007) 92(2):416-417.
   PubMed Web of Science ®Google Scholar
• SHAMES D, GASSMAN A, HANDELSMAN H: Commentary: guideline for male testosterone therapy: a regulatory. J. Clin. Endocrinol. Metab. (2007) 92(2):414-415.
   PubMed Web of Science ®Google Scholar
• YASSIN AA, SAAD F: Treatment of sexual dysfunction of hypogonadal patients with long-acting testosterone undecanoate (Nebido). World J. Urol. (2006) 24(6):639-644.
   PubMed Web of Science ®Google Scholar
• HARLE L, BASARIA S, DOBS AS: Nebido: a long-acting injectable testosterone for the treatment of male hypogonadism. Expert Opin. Pharmacother. (2005) 6(10):1751-1759.
   PubMed Web of Science ®Google Scholar
• CHATTERJEE R, KOTTARIDIS PD, MCGARRIGLE HH, LINCH DC: Management of erectile dysfunction by combination therapy with testosterone and sildenafil in recipients of high-dose therapy for haematological malignancies. Bone Marrow Transplant. (2002) 29(7):607-610.
   PubMed Web of Science ®Google Scholar
• GREENSTEIN A, MABJEESH NJ, SOFER M et al.: Does sildenafil combined with testosterone gel improve erectile dysfunction in hypogonadal men in whom testosterone supplement therapy alone failed? J. Urol. (2005) 173(2):530-532.
   PubMed Web of Science ®Google Scholar
• ROCHIRA V, BALESTRIERI A, MADEO B, GRANATA AR, CARANI C: Sildenafil improves sleep-related erections in hypogonadal men: evidence from a randomized, placebo-controlled, crossover study of a synergic role for both testosterone and sildenafil on penile erections. J. Androl. (2006) 27(2):165-175.
   PubMed Web of Science ®Google Scholar